Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glipizide + insulin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
A combination therapy used for treating type 2 diabetes mellitus, particularly in patients with secondary failure on oral hypoglycemic agents alone. Glipizide is a sulfonylurea that stimulates insulin release from the pancreas and helps the body use insulin efficiently. When combined with insulin therapy, it can increase insulin-mediated peripheral glucose disposal, though it carries an increased risk of hypoglycemia.
02
Targets
INSR (Insulin receptor)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on glipizide + insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glipizide + insulin.